191327-87-4

Basic information

• Product Name: tert-butyl 4-benzyl-4-hydroxypiperidine-1-carboxylate
• Synonyms: tert-butyl 4-benzyl-4-hydroxypiperidine-1-carboxylate;N-BOC-4-benzyl-4-hydroxypiperidine;4-Hydroxy-4-(phenylmethyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
• CAS NO: 191327-87-4
• Molecular Formula: C₁₇H₂₅NO₃
• Molecular Weight: 291.3853
• Mol File: 191327-87-4.mol

Chemical Properties

• Melting Point: 87-88℃
• Appearance: /
• CAS DataBase Reference: tert-butyl 4-benzyl-4-hydroxypiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-benzyl-4-hydroxypiperidine-1-carboxylate(191327-87-4)
• EPA Substance Registry System: tert-butyl 4-benzyl-4-hydroxypiperidine-1-carboxylate(191327-87-4)

Safety Data

• Hazardous Substances Data: 191327-87-4(Hazardous Substances Data)

Upstream product

• 51135-96-7 4-benzyl-4-hydroxypiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1589-82-8 phenylmagnesium bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 100-39-0 benzyl bromide 
• 6921-34-2 benzylmagnesium chloride 

Downstream Products

• 191327-88-5 1-tert-butyloxycarbonyl-4-benzyl-4-fluoropiperidine 
• 1623011-33-5 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(thieno[3,2-b]pyridin-7-yl)urea 
• 1623011-16-4 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylthieno-[3,2-b]pyridin-7-yl)urea 
• 1623011-18-6 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(3-bromothieno-[3,2-b]pyridin-7-yl)urea 
• 51135-96-7 4-benzyl-4-hydroxypiperidine 
• 1623011-20-0 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(5-methylthieno-[3,2-b]pyridin-7-yl)urea 

Relevant articles and documents

Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element

There are currently no approved vaccines or small molecule therapeutics available for the prophylaxis or treatment of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infections. MERS-CoV 3CL protease is essential for viral replication; consequently, it is an attractive target that provides a potentially effective means of developing small molecule therapeutics for combatting MERS-CoV. We describe herein the structure-guided design and evaluation of a novel class of inhibitors of MERS-CoV 3CL protease that embody a piperidine moiety as a design element that is well-suited to exploiting favorable subsite binding interactions to attain optimal pharmacological activity and PK properties. The mechanism of action of the compounds and the structural determinants associated with binding were illuminated using X-ray crystallography.

COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and/or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. C

Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin

Matriptase and hepsin are type II transmembrane serine proteases (TTSPs). Along with related S1 trypsin like serine protease HGFA (hepatocyte growth factor activator), their unregulated proteolytic activity has been associated with cancer including tumor progression and metastasis. These three proteases have two substrates in common, hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), the ligands for MET and recepteur d'origine nantais (RON) receptor tyrosine kinases. Mechanism-based tetrapeptide and benzamidine inhibitors of these proteases have been shown to block HGF/MET and MSP/RON cancer cell signaling. Herein, we have rationally designed a new class of peptidomimetic hybrid small molecule piperidine carbamate dipeptide inhibitors comparable in potency to much larger tetrapeptides. We have identified multiple compounds which have potent activity against matriptase and hepsin and with excellent selectivity over the off-target serine proteases factor Xa and thrombin.

COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASES

The present invention refers to relates to compound for treating inflammatory diseases, said formula I compounds represented, such as, a pharmaceutically acceptable salts, or their, or a hydrate thereof is characterized in that the, polymerized. According to the present invention, interacting with-path 5-LOX a compound or interference, in particular 5- oh height[...]width it recovers sourly, in sacrifice, which display inhibitory effects can be provides compounds having. (by machine translation)

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists

The preparation and SAR profile of thieno[3,2-b]pyridinyl urea derivatives as novel and potent urotensin-II receptor antagonists are described. An activity optimization study, probing the effects of substituents on thieno[3,2-b]pyridinyl core and benzyl group of the piperidinyl moiety, led to the identification of p-fluorobenzyl substituted thieno[3,2-b]pyridinyl urea 6n as a highly potent UT antagonist with an IC50 value of 13 nM. Although 6n displays good metabolic stability and low hERG binding activity, it has an unacceptable oral bioavailability.

ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS

The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors, hi particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.

N-acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.

N-Acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula Are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.

Substituted piperidine derivatives as selective agonists of 5-HT receptors

PCT No. PCT/GB96/02765 Sec. 371 Date May 13, 1998 Sec. 102(e) Date May 13, 1998 PCT Filed Nov. 13, 1996 PCT Pub. No. WO97/18202 PCT Pub. Date May 22, 1997A compound of formula (I), or a salt or prodrug thereof, is described, wherein G is attached at posit